TY  - GEN
N2  - This report examines the role that patents play in access to pharmaceuticals in the HIV/AIDS crisis of sub-Saharan Africa. The report aims to provide unbiased information about the international patent regime, the current patent status of certain HIV/AIDS drugs in sub-Saharan Africa and opportunities that exist through flexibility in international patent law that may help to improve access to HIV/AIDS drugs in that region. The report concludes that providing state-of-the-art HIV/AIDS therapies to patients in poor countries requires two kinds of subsidies. The first is the indirect subsidy which consumers in developed countries pay in the form of higher prices for patented drugs. The patent incentive in countries such as the United States induces the free market to test and develop new products. Without the patent incentive, life- sustaining AIDS therapies would simply be unavailable even to the wealthiest consumers. The second kind of subsidy is direct funding of the treatment infrastructure and the purchase of drugs for patients in poor countries by the governments of developed countries acting in concert with one another through international programs such as UNAIDS.
DO  - 10.34667/tind.12739
DO  - doi
AB  - This report examines the role that patents play in access to pharmaceuticals in the HIV/AIDS crisis of sub-Saharan Africa. The report aims to provide unbiased information about the international patent regime, the current patent status of certain HIV/AIDS drugs in sub-Saharan Africa and opportunities that exist through flexibility in international patent law that may help to improve access to HIV/AIDS drugs in that region. The report concludes that providing state-of-the-art HIV/AIDS therapies to patients in poor countries requires two kinds of subsidies. The first is the indirect subsidy which consumers in developed countries pay in the form of higher prices for patented drugs. The patent incentive in countries such as the United States induces the free market to test and develop new products. Without the patent incentive, life- sustaining AIDS therapies would simply be unavailable even to the wealthiest consumers. The second kind of subsidy is direct funding of the treatment infrastructure and the purchase of drugs for patients in poor countries by the governments of developed countries acting in concert with one another through international programs such as UNAIDS.
T1  - Patent protection and access to HIV/AIDS pharmaceuticals in Sub-Saharan Africa.
L1  - https://tind.wipo.int/record/12739/files/wipo-pub-patent-protection-and-access-to-HIV-AIDS-pharmaceuticals-in-sub-saharan-Africa.pdf
LA  - eng
ID  - 12739
L4  - https://tind.wipo.int/record/12739/files/wipo-pub-patent-protection-and-access-to-HIV-AIDS-pharmaceuticals-in-sub-saharan-Africa.pdf
KW  - Patents
KW  - WIPO - TRIPS : RELATIONSHIP
KW  - PATENTS : PATENTABILITY : PHARMACEUTICAL PRODUCTS : AFRICA
KW  - PATENT POLICY : US, EU
KW  - PARALLEL IMPORTS
KW  - COMPULSORY LICENSING
KW  - ARIPO
KW  - OAPI
TI  - Patent protection and access to HIV/AIDS pharmaceuticals in Sub-Saharan Africa.
L2  - https://tind.wipo.int/record/12739/files/wipo-pub-patent-protection-and-access-to-HIV-AIDS-pharmaceuticals-in-sub-saharan-Africa.pdf
LK  - https://tind.wipo.int/record/12739/files/wipo-pub-patent-protection-and-access-to-HIV-AIDS-pharmaceuticals-in-sub-saharan-Africa.pdf
UR  - https://tind.wipo.int/record/12739/files/wipo-pub-patent-protection-and-access-to-HIV-AIDS-pharmaceuticals-in-sub-saharan-Africa.pdf
ER  -